|
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease Clinical research trials and Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease. Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease clinical trial. Human subjects often obtain the finest healthcare possible for their Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease  Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
For Condition: Lymphocytic Lymphoma,Myeloid Leukemia,Hodgkin's Disease,Skin Cancer,Plasma Cell Tumor
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , M.D. Anderson Cancer Center
Synopsis: RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill lymphoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-12 in treating patients with previously treated non-Hodgkin's lymphoma or Hodgkin's disease.
Details: OBJECTIVES: I. Determine the response rate of interleukin-12 in previously treated patients with non-Hodgkin's lymphoma or Hodgkin's disease. PROTOCOL OUTLINE: Patients are stratified according to disease characteristics: low grade non-Hodgkin's lymphoma (follicular small cleaved, follicular mixed, small lymphocytic, and variants) versus intermediate grade non-Hodgkin's lymphoma (follicular large, diffuse large, diffuse mixed, immunoblastic, peripheral T-cell, and mantle cell) versus Hodgkin's disease. Patients receive interleukin-12 subcutaneously twice a week. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 36-105 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 16 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Previously treated non-Hodgkin's lymphoma (all histologies except lymphoblastic and Burkitt's lymphoma) or Hodgkin's disease - Maximum of 4 previous treatment regimens - Measurable disease - No CNS involvement A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. --Prior/Concurrent Therapy-- Biologic therapy: - No prior allogeneic bone marrow or stem cell transplant - At least 3 weeks since prior biologic therapy for lymphoma Chemotherapy: At least 3 weeks since prior chemotherapy for lymphoma Endocrine therapy: - No concurrent steroid therapy - At least 3 weeks since prior endocrine therapy for lymphoma Radiotherapy: At least 3 weeks since prior radiotherapy for lymphoma Surgery: At least 2 weeks since prior surgery --Patient Characteristics-- Age: 16 and over Performance status: - Zubrod 0-1 - Karnofsky 80-100% Life expectancy: At least 12 weeks Hematopoietic: - Platelet count at least 75,000/mm3 - Absolute neutrophil count greater than 1500/mm3 - Lymphocyte count greater than 500/mm3 - Hemoglobin at least 8.0 g/dL Hepatic: - Bilirubin less than 1.5 mg/dL - SGOT/SGPT less than 2 times normal Renal: - Creatinine no greater than 1.6 mg/dL - Creatinine clearance at least 60 mL/min Cardiovascular: No severe cardiovascular disease including active ischemic heart disease, congestive heart failure, or major arrhythmias Pulmonary: No severe pulmonary disease including dyspnea with moderate to severe exertion Other: - HIV negative - No active infection - Not pregnant or nursing - Fertile patients must use adequate contraception - No clinically significant autoimmune disease (e.g. rheumatoid arthritis) - No clinically significant gastrointestinal bleeding or uncontrolled peptic ulcer
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AnasYounes, Study Chair, M.D. Anderson Cancer Center
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009
United States
Additional Information:
Study ID Numbers: CDR0000066067; MDA-DM-97073,NCI-T97-0050
Study Start Date: February 1998
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003210
Other Plasma Cell Tumor Studies:
1. Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
2. Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
3. Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
4. Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
5. Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
Related Studies:
Other Plasma Cell Tumor Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
|
|
|
|
|
|
|
|
